Landiolol and Organ Failure in Patients With Septic Shock: The STRESS-L Randomized Clinical Trial
Primary resultResult — go to the resultMD 0.75 95% CI −0.49 to 2.0- early termination
- Stopped prematurely on advice of the independent data monitoring committee: unlikely to demonstrate benefit and possible harm
Authors' conclusion
Among patients with septic shock with tachycardia and treated with norepinephrine for more than 24 hours, an infusion of landiolol did not reduce organ failure measured by the SOFA score over 14 days from randomization.
Study context
- Population
- Adults with tachycardia (heart rate ≥95/min) and established septic shock treated ≥24 hours with norepinephrine (≥0.1 μg/kg/min), 40 UK NHS ICUs37% of planned 340
- Participants
- 126 adults
- Comparison
- Landiolol infusion vs standard care
- Landiololn = 63
- Standard caren = 63reference
- Primary endpoint
- Mean Sequential Organ Failure Assessment (SOFA) score from randomisation through 14 days
- Follow-up
- 14 days
Methodological detailsopen-label, multicentre
- Open-label
- Multicentre
Primary result
As reported in the abstract
MD
0.75
95% CI −0.49 to 2.0
P = 0.24
By group
Landiolol
8.8
mean · SD 3.9
Standard care
8.1
mean · SD 3.2
Landiolol vs Standard care
MD 0.75 (95% CI −0.49 to 2.0); P = 0.24
Secondary outcomes
| Outcome | Landiolol | Standard care | Absolute difference (95% CI) | P value | |
|---|---|---|---|---|---|
| Mortality · day 28 | 37.1% | 25.4% | 11.7% (−4.4% to 27.8%) | P = 0.16 | |
| Mortality · day 90 | 43.5% | 28.6% | 15% (−1.7% to 31.6%) | P = 0.08 | |
| −2002040Difference (linear scale) |
- Mortality: 23 of 62 vs 16 of 63
- Mortality: 27 of 62 vs 18 of 63
Safety
Patients with at least one adverse event
- No differences between groups
Original publication
Landiolol and Organ Failure in Patients With Septic Shock: The STRESS-L Randomized Clinical Trial. JAMA. Published 7 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →